- Home
- QGEN
QGEN
Qiagen N.V.
as 12-20-2024 4:00pm EST
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
| Founded: | 1986 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 9.5B | IPO Year: | 1996 |
| Target Price: | $51.42 | AVG Volume (30 days): | 865.8K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 0.41 | EPS Growth: | -72.27 |
| 52 Week Low/High: | $39.03 - $47.44 | Next Earning Date: | 02-04-2025 |
| Revenue: | $1,966,174,000 | Revenue Growth: | 0.62% |
| Revenue Growth (this year): | 2.78% | Revenue Growth (next year): | 5.69% |
Latest Qiagen N.V. News
QGEN Breaking Stock News: Dive into QGEN Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Zacks
9 days ago
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
Zacks
9 days ago
QIAGEN Stock Gains Following the Latest Launch of IPA Interpret
Business Wire
10 days ago
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
Zacks
10 days ago
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?
Zacks
13 days ago
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
Zacks
16 days ago
Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?
MT Newswires
17 days ago
Qiagen Reports Over 1,000 Placements of EZ2 Connect Instrument Globally
Compare QGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QGEN Qiagen N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.